BOTTA, CIRINO
 Distribuzione geografica
Continente #
NA - Nord America 216
EU - Europa 105
AS - Asia 6
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
SA - Sud America 1
Totale 335
Nazione #
US - Stati Uniti d'America 209
IT - Italia 63
GB - Regno Unito 15
SE - Svezia 12
CA - Canada 7
EU - Europa 4
NL - Olanda 4
ES - Italia 3
IN - India 3
CN - Cina 2
FI - Finlandia 2
NZ - Nuova Zelanda 2
PL - Polonia 2
AU - Australia 1
BY - Bielorussia 1
CL - Cile 1
CZ - Repubblica Ceca 1
DE - Germania 1
HK - Hong Kong 1
PT - Portogallo 1
Totale 335
Città #
Chandler 47
London 14
Princeton 13
Chicago 12
Lawrence 12
Ashburn 9
Catanzaro 8
Ottawa 6
Wilmington 5
Des Moines 4
Lamezia Terme 4
Redmond 4
Utrecht 4
Barcelona 3
Castrovillari 3
Naples 3
Redwood City 3
Rome 3
Rosarno 3
San Antonio 3
Chennai 2
Cortale 2
Grottaglie 2
Helsinki 2
Leawood 2
Milan 2
Padova 2
Santo Stefano di Rogliano 2
Auckland 1
Bari 1
Catania 1
Clearwater 1
Crotone 1
Filadelfia 1
Hanover 1
Hong Kong 1
Kansas City 1
Los Angeles 1
Mascalucia 1
Minsk 1
Norwalk 1
Oristano 1
Ovada 1
Phoenix 1
Rende 1
Roccella Jonica 1
Saint Louis 1
Settingiano 1
Sydney 1
Toronto 1
Trieste 1
Turin 1
Vancouver 1
Washington 1
Totale 205
Nome #
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 39
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells. 33
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 33
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 27
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 25
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 22
miR-22 suppresses DNA ligase III addiction in multiple myeloma 22
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 21
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 20
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 20
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 17
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 16
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 14
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 13
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 12
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 11
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 10
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 10
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 7
Totale 372
Categoria #
all - tutte 3.869
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.869


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 2 1 0 1 0 2 0 6
2020/202149 4 0 3 2 1 7 2 5 12 10 3 0
2021/202267 0 0 1 11 7 2 7 9 8 9 13 0
2022/2023151 25 16 16 5 12 14 6 7 26 7 13 4
2023/202493 24 13 5 18 9 19 0 0 3 2 0 0
Totale 372